Research
Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer
Author affiliations
1 Department of Respiratory Medicine, Second Affiliated Hospital of Medical School, Xi'an Jiaotong University, N-710000 Xi'an, China
2 Medical Department of Second Hospital of Xi'an, N-710000 Xi'an, China
Citation and License
Diagnostic Pathology 2010, 5:60 doi:10.1186/1746-1596-5-60
Published: 20 September 2010Abstract
Background
The purpose of this study is to discover potential biomarkers in serum for the detection of small cell lung cancer (SCLC).
Methods
74 serum samples including 30 from SCLC patients and 44 from healthy controls were analyzed using ClinProt system combined with matrix-assisted laser desorption/ionization time-of-flight masss spectrometry (MALDI-TOF-MS). ClinProt software and genetic algorithm analysis selected a panel of serum markers that most efficiently predicted which patients had SCLC.
Results
The diagnostic pattern combined with 5 potential biomarkers could differentiate SCLC patients from healthy persons, with a sensitivity of 90%, specificity of 97.73%. Remarkably, 88.89% of stage I/II patients were accurately assigned to SCLC.
Conclusions
Anchorchip-time-of-flight spectrometry technology will provide a highly accurate approach for discovering new biomarkers for the detection of SCLC.
